CO2022008690A2 - Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso - Google Patents
Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de usoInfo
- Publication number
- CO2022008690A2 CO2022008690A2 CONC2022/0008690A CO2022008690A CO2022008690A2 CO 2022008690 A2 CO2022008690 A2 CO 2022008690A2 CO 2022008690 A CO2022008690 A CO 2022008690A CO 2022008690 A2 CO2022008690 A2 CO 2022008690A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- delta
- methods
- heterocyclic compounds
- desaturase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939821P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/062020 WO2021108408A1 (en) | 2019-11-25 | 2020-11-24 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022008690A2 true CO2022008690A2 (es) | 2022-06-30 |
Family
ID=73855555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0008690A CO2022008690A2 (es) | 2019-11-25 | 2022-06-22 | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11512097B2 (https=) |
| EP (1) | EP4065223A1 (https=) |
| JP (2) | JP7254246B2 (https=) |
| KR (2) | KR20230154292A (https=) |
| CN (2) | CN114728167B (https=) |
| AR (1) | AR120556A1 (https=) |
| AU (1) | AU2020392087B2 (https=) |
| BR (1) | BR112022010054A2 (https=) |
| CA (1) | CA3162281A1 (https=) |
| CL (2) | CL2022001357A1 (https=) |
| CO (1) | CO2022008690A2 (https=) |
| CR (1) | CR20220308A (https=) |
| IL (1) | IL293191B2 (https=) |
| JO (1) | JOP20220125A1 (https=) |
| MX (1) | MX2022006281A (https=) |
| PE (1) | PE20231097A1 (https=) |
| PH (1) | PH12022551282A1 (https=) |
| SA (1) | SA522432710B1 (https=) |
| TW (2) | TWI815061B (https=) |
| UY (1) | UY38971A (https=) |
| WO (1) | WO2021108408A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11220510B2 (en) * | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| CN114728167B (zh) | 2019-11-25 | 2024-03-19 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
| CN115557903A (zh) * | 2022-09-27 | 2023-01-03 | 山东潍坊润丰化工股份有限公司 | 一种特草定的制备方法 |
| CN120435293A (zh) | 2022-11-23 | 2025-08-05 | 安进公司 | 选择使用fads-1抑制剂治疗fads1介导的疾病或障碍的患者 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3130633A1 (de) | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| DE3786365T2 (de) | 1986-04-07 | 1993-10-21 | Ihara Chemical Ind Co | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-on-Derivate und diese enthaltende Gartenbau- und landwirtschaftliche Fungizidmittel. |
| EP0948496A2 (en) | 1996-12-05 | 1999-10-13 | Amgen inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6537998B1 (en) * | 1999-10-15 | 2003-03-25 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| MXPA02003614A (es) | 1999-10-15 | 2002-10-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos.. |
| TW200401770A (en) | 2002-06-18 | 2004-02-01 | Sankyo Co | Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof |
| JP2004107228A (ja) | 2002-09-17 | 2004-04-08 | Nippon Nohyaku Co Ltd | 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤 |
| AR049769A1 (es) | 2004-01-22 | 2006-09-06 | Novartis Ag | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US7906645B2 (en) | 2004-12-24 | 2011-03-15 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
| JP2008546843A (ja) | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| WO2007027012A1 (en) | 2005-07-18 | 2007-03-08 | Samsung Electronics Co., Ltd. | Video coding method and apparatus for reducing mismatch between encoder and decoder |
| US20080200480A1 (en) | 2005-07-27 | 2008-08-21 | Basf Aktiengesellschaft | Fungicidal 6-Phenyltriazolopyrimidinylamines |
| US20080312078A1 (en) | 2005-07-27 | 2008-12-18 | Basf Aktiengesellschaft | 6-Phenyl-Pyrazolopyrimidine-7-Ylamine Fungicides |
| CN101227819A (zh) | 2005-07-27 | 2008-07-23 | 巴斯福股份公司 | 杀真菌剂5-甲基-6-苯基三唑并嘧啶基胺 |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| CA2664375A1 (en) | 2006-09-28 | 2008-04-03 | Novartis Ag | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use |
| CA2665476A1 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| US8211828B2 (en) | 2007-01-19 | 2012-07-03 | Basf Se | Fungicidal mixtures of 1-methylpyrazol-4-ylcarboxanilides and azolopyrimidinylamines |
| EP2131658A2 (en) | 2007-01-30 | 2009-12-16 | Basf Se | Method for improving plant health |
| US8461077B2 (en) | 2007-03-23 | 2013-06-11 | Basf Se | Combinations of active substances |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009124259A1 (en) | 2008-04-04 | 2009-10-08 | Cv Therapeutics, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| US20100099561A1 (en) | 2008-10-15 | 2010-04-22 | E.I. Du Pont De Nemours And Company | Heterobicyclic alkylthio-bridged isoxazolines |
| US20100190747A1 (en) | 2009-01-27 | 2010-07-29 | Hideo Suzuki | Fused ring compound and use thereof |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| WO2011114148A1 (en) * | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| WO2012011592A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2013177538A2 (en) | 2012-05-24 | 2013-11-28 | Colorado State University Research Foundation | Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease |
| KR20150130491A (ko) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
| EP3041474B1 (en) | 2013-09-05 | 2020-03-18 | Genentech, Inc. | Antiproliferative compounds |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| WO2015135094A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CA2946702C (en) | 2014-04-23 | 2022-06-28 | Mitsubishi Tanabe Pharma Corporation | Bicyclic or tricyclic heterocyclic compound |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| JP6791717B2 (ja) | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP2017091808A (ja) | 2015-11-10 | 2017-05-25 | 株式会社フジクラ | 酸化物超電導線材の製造方法及び超電導コイルの製造方法 |
| WO2017112678A1 (en) | 2015-12-21 | 2017-06-29 | Rima Mcleod | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
| JP6832430B2 (ja) | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN106749271B (zh) | 2016-12-07 | 2019-04-05 | 青岛科技大学 | 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| WO2018229683A1 (en) | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| SG11202002218VA (en) | 2017-09-15 | 2020-04-29 | Aduro Biotech Inc | Pyrazolopyrimidinone compounds and uses thereof |
| CN114728167B (zh) | 2019-11-25 | 2024-03-19 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
-
2020
- 2020-11-24 CN CN202080081465.8A patent/CN114728167B/zh active Active
- 2020-11-24 CR CR20220308A patent/CR20220308A/es unknown
- 2020-11-24 KR KR1020237037455A patent/KR20230154292A/ko not_active Ceased
- 2020-11-24 AU AU2020392087A patent/AU2020392087B2/en active Active
- 2020-11-24 PH PH1/2022/551282A patent/PH12022551282A1/en unknown
- 2020-11-24 KR KR1020227021152A patent/KR102598203B1/ko active Active
- 2020-11-24 JP JP2022529556A patent/JP7254246B2/ja active Active
- 2020-11-24 CN CN202410291075.3A patent/CN118161500A/zh active Pending
- 2020-11-24 CA CA3162281A patent/CA3162281A1/en active Pending
- 2020-11-24 EP EP20828193.1A patent/EP4065223A1/en active Pending
- 2020-11-24 IL IL293191A patent/IL293191B2/en unknown
- 2020-11-24 PE PE2022000849A patent/PE20231097A1/es unknown
- 2020-11-24 BR BR112022010054A patent/BR112022010054A2/pt unknown
- 2020-11-24 US US17/103,389 patent/US11512097B2/en active Active
- 2020-11-24 WO PCT/US2020/062020 patent/WO2021108408A1/en not_active Ceased
- 2020-11-24 MX MX2022006281A patent/MX2022006281A/es unknown
- 2020-11-25 UY UY0001038971A patent/UY38971A/es not_active Application Discontinuation
- 2020-11-25 TW TW109141315A patent/TWI815061B/zh active
- 2020-11-25 TW TW112142068A patent/TWI867822B/zh active
- 2020-11-25 AR ARP200103274A patent/AR120556A1/es unknown
-
2021
- 2021-03-16 US US17/203,457 patent/US20210221824A1/en not_active Abandoned
-
2022
- 2022-05-23 JO JOP/2022/0125A patent/JOP20220125A1/ar unknown
- 2022-05-24 CL CL2022001357A patent/CL2022001357A1/es unknown
- 2022-05-24 SA SA522432710A patent/SA522432710B1/ar unknown
- 2022-06-22 CO CONC2022/0008690A patent/CO2022008690A2/es unknown
- 2022-11-18 US US18/056,863 patent/US12448396B2/en active Active
-
2023
- 2023-03-27 JP JP2023049452A patent/JP7698676B2/ja active Active
- 2023-08-22 CL CL2023002486A patent/CL2023002486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| MX2023012725A (es) | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| CR20190301A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| NI201100137A (es) | Derivados de sulfonamida | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CO6290687A2 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| ECSP11011412A (es) | Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso | |
| CO6300939A2 (es) | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada | |
| ECSP109953A (es) | Derivados de piridazinona | |
| UY31906A (es) | Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias. | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| AR078613A1 (es) | Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores. | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| UY38972A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
| GT201100039A (es) | Agentes antifúngicos |